Amplexa genetics and CeGaT enter into collaborative partnership

16th November 2012

CeGaT GmbH and Amplexa Genetics A/S are pleased to announce they are entering into a collaborative partnership to provide a wider range of clinical genetic testing services to increase the number of disorders that they can offer to physicians and their patients.

The partnership will see both companies exchanging their expertise and knowledge as well as validated genetic tests for their respective patients. One of the main areas of the collaboration will involve Next Generation Sequencing (NGS) technologies as well as the traditional method of Sanger Sequencing to analyze patient’s genes to determine if they contain mutations that are linked to particular diseases. The two companies will complement each other’s platform technologies and QC methods to ensure high quality and reproducible results that they are both well known for. Both companies will also exchange knowledge and expertise in the area of bioinformatics data analysis to enable them to use state of the art algorithmic software methods to pull out the mutations from the sequence data. Together, both companies intend to establish a global footprint of expertise that will allow physicians and patients to find value, quality and genetic counseling for a large repertoire of genetic disease.

ABOUT GENETIC TESTING
A genetic test is a test that can be performed using a number of different technologies that enable the “reading” of regions of a patient’s DNA. Once an entire region or regions of DNA have been read, the sequence data needs to be analyzed using specialist software that is able to pull out the mistakes or mutations within the DNA sequences. Based on the mutations that are found, the expert geneticists are able to interpret whether there is a clinical significance of the mutation and there is a likelihood of developing a particular disease. Genetic counseling must then be provided to a patient who has been diagnosed with a clinically relevant mutation so that the patient is able to understand and grasp the implications of such a genetic diagnosis. In some instances, this may lead to certain treatment regimes or further genetic testing on family members to ascertain the inheritance of the disease. For more information please see the Amplexa Genetics or CeGaT website.

ABOUT CeGaT
The CeGaT GmbH, Center for Genomics and Transcriptomics was founded in 2009 and is a service provider for DNA and RNA sequencing of humans, animals, plants, and microorganisms. CeGaT is the first company worldwide that was able to offer Diagnostic Panels for molecular testing. CeGaT Diagnostic Panels enable to investigate all known genes which are disease relevant simultaneously and hence the probability to confirm a diagnosis is significantly higher. CeGaT uses the latest available technologies and applies both conventional Sanger-Sequencing and Next-Generation-Sequencing. Depending on the particular project, CeGaT deciphers DNA and RNA, genes, exomes, transcriptomes, or complete genomes. If required, an interpretation of the
results and complete bioinformatic analysis can be provided. Thus CeGaT GmbH is a service provider for medical doctors, researchers, clinics, as well as private persons. CeGaT laboratory is accredited as a molecular human genetic diagnostics laboratory according to DIN EN ISO 15189:2007 and is regularly participating to external quality control assessments from the EMQN or German society of human genetics. CeGaT was awarded “Best German Start-Up Company 2011”
Website: www.cegat.de
Email: info@cegat.de

Gerald Tomenendal, Head of Strategy & Sales at CeGaT stated: “CeGaT and Amplexa have signed a strategic collaboration agreement to promote complementary services in Germany and in Denmark. This collaboration is in line with CeGaT’s strategy to expand this industry leading platform services worldwide. Amplexa is an ideal partner for us. Their high quality standard and services fit well with our current offerings and with our business philosophy – to provide premium diagnostic services to patients to find the causative reason for the disease. We are very pleased to partner with Amplexa by sharing expertise and knowledge. This will lead to broader services in Western Europe and higher satisfaction among physicians and patients. We are looking forward to work together and make this collaboration a successful collaboration.”

ABOUT AMPLEXA
Amplexa Genetics A/S was founded in 2006 and is an expert in efficient molecular genetic testing. The company consists of experienced researchers equipped with the latest technologies who provide their expertise to the genetic health care sector. Amplexa Genetics provides a wide range of traditional molecular genetic tests using Sanger sequencing and also offers Next Generation Sequencing panels to physicians and private patients together with a genetic counseling service when required. The service is reliable and cost effective with the highest standards of quality. Amplexa Genetics is participating in the European Molecular Genetics Quality Network (EMQN) 2008 - 2012 quality assessment schemes for mutation scanning and sequencing (External Quality Assessment - EQA).
Website: www.amplexa.com
Email: info@amplexa.com

Elisabetta Fineschi, Business Development Director at Amplexa Genetics A/S commented “With the requirement for stringently regulated clinical genetics services and an ever increasing patient need, Amplexa and CeGaT have recognized that they have the know-how, reputation, quality and reproducibility to leverage their relationship to offer real value and knowledge for their patients and their physicians. This knowledge is relayed to the patients and physicians by our genetic counselors and allows the patients and their families to make critical decisions that will impact on their lives. With this in mind Amplexa acknowledges that our work will always be expanding to include new genetic conditions which are needed by the patients. For this reason, we will strategically expand our partnerships and this collaboration with CeGaT is a big step in that direction.”